Galderma initiates two new clinical trials investigating nemolizumab in patients with Systemic Sclerosis and Chronic Pruritus of Unknown Origin Press release
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years Press release
RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years Press release
Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology® Press release
Galderma launches Sculptra® in China, further fueling its growth into one of the fastest growing aesthetics markets Press release
AMWC 2025: Galderma pushes the innovation frontier with updates from its unparalleled portfolio designed to meet the needs of the aesthetic community Press release
Galderma successfully placed an inaugural EUR 500 million single tranche Eurobond and new dual tranche CHF 435 million CHF bonds Press release
AAD 2025: Galderma to present extensive updates from across its dermatology portfolio, demonstrating its category leadership and strong momentum Press release
Galderma’s Nemluvio® (nemolizumab) granted marketing authorization in the United Kingdom and Switzerland for moderate-to-severe atopic dermatitis and prurigo nodularis Press release
